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Sumnlary 
The mouse proto-oncogene Pim-1, which encodes two cytoplasmic serine-threonine-specific  protein 
kinases, is frequently activated by proviral insertion in murine leukemia virus-induced hematopoietic 
tumors.  Transgenic mice overexpressing Pim-1  show a low incidence of spontaneous T  cell 
lymphomas, whereas null mutant mice lack an obvious phenotype. We have analyzed the early 
B lymphoid compartment from both null mutant and El~-Pim-1 transgenic mice. The level of 
Pim-1 expression appears to be a determining factor in the ability of these cells to respond to 
the growth factors interleukin 7 (IL-7) and SF (steel factor). The impaired response in null mutant 
mice could be rescued by introduction of a functional Pim-1 transgene. Moreover, overexpression 
of Pim-1 facilitates the derivation of primitive lymphoid cell lines that are dependent on combined 
stimulation with IL-7 and SF or insulin-like growth factor 1.  These results for the first time 
identify the involvement of Pim-1 in a normal cellular function, as an important regulator of 
early B lymphopoiesis in mice. 
T 
he Pim-1 gene was originally identified as a common 
insertion site in Moloney MuLV (MoMuLV)l-induced 
T  cell lymphomas in mice (1, 2).  Subsequently, it has also 
been found activated in MoMuLV-induced B call lymphomas 
(3)  and Friend virus-induced erythroleukemias (4). 
The mouse Pim-1 gene encodes two proteins by alterna- 
tive initiation at AUG (34 kD) or CUG (44 kD). Usage of 
the latter is not apparent in humans (5). Although the human 
protein has been reported to phosphorylate tyrosine residues 
(6), more recent data conclusively show that both the mouse 
(5) and human (5,  7,  8) Pim-1 proteins exclusively exhibit 
serine/threonine-dependent protein kinase activity. Both pro- 
teins are localized in the cytoplasm and are short-lived, with 
half-life values of 5-10 rain for the 34 kD and '~,45 rain for 
the 44-kD protein (5).  Both murine and human Pim-1 are 
predominantly expressed in hematopoietic tissues (9, 10) where 
mRNA and protein are mitogen inducible (11-13). 
The gene's oncogenic potential was proven in E/~-Pim-1 
transgenic mice, which showed a low inddence of T cell lym- 
phomas (9).  The low incidence and variable latency period 
indicates that overexpression by itself is insufficient for trans- 
formation.  This was confirmed by exposing mice to viral 
1Abbreviations used in  this paper: CFC,  colony-forming  cell;  CM, 
conditioned medium; IGF-1, insulin-like growth factor; LTC, long-term 
culture; MoMuLV, Moloney murine leukemia virus; SF, steel factor. 
(MoMuLV) or chemical (N-ethyl-N-nitrosourea) carcinogenic 
agents. In both cases, lymphomas developed much faster in 
transgenic animals (9,  14). In nearly all EIz-Pim-1 tumors, 
activation of c-myc or n-myr was observed. The capacity of 
Pim-1 and c-myc to synergize in lymphomagenesis was most 
convincingly shown in crosses of E/~-myc and E#-Pira-1 trans- 
genic mice. Coexpression of both transgenes caused the de- 
velopment ofpre-B cell leukemias in utero (15), making this 
the strongest cooperation seen between two oncogenes in 
vivo to date. 
Pim-1 is highly conserved between mammals (2, 10, 16-18). 
Null mutants, however, display a surprisingly limited pheno- 
type (19, 20) apart from an impaired IL-3 response (21). As 
our earlier studies showed that Pira-1 can predispose to pre- 
B cell neoplasias, we have analyzed the early B lymphoid com- 
partment from bone marrow of mice expressing different levels 
of Pim-1. Expression level-dependent differences were indeed 
detected. 
Materials  and Methods 
Mutant Pim-I Mice.  The Pim-1 null mutants,  lacking part of 
the coding region, were as described before (21). The null alleles 
were maintained on a 129/Ola (inbred) or a 129/Ola  x  BALB/c 
(outbred) background.  The Et~-Pim-1 transgenic, founderline 64 
mice have also been described before (10). The transgene consists 
of a genomic Pim-1 clone with two copies of the Ig E/~ enhancer 
located upstream of the start site and a MoMuLV LTR in the 3' 
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eloid cells.  The transgene  was  introduced into  (CBA/BrA  x 
C57BL/LiA)F1 zygotes and the resulting transgenics were back- 
crossed  with  (CBA/BrA  x  C57BL/LiA)F1,  C57BL/LiA,  or 
C57BL/6 mice. The WT-Pim-1 transgenic mice, founderline 4550, 
were made by introduction of an "~11-kb genomic EcoRI frag- 
ment of Pim-1 into FVB zygotes. The genotype of all the mutant 
mice was monitored by Southern analysis of tail-tip DNA, according 
to Laird et al.  (22). 
Protein Analysis.  Analysis of the Pim-1 proteins was essentially 
as described  (5) with some modifications. Briefly, cells were sus- 
pended in lysis buffer (20 mM Hpes, pH 7.0, 30 mM NaC1, 5 mM 
MgCI2,  14  mM  B-ME,  1%  aprotinin,  1  mM  PMSF,  1  mM 
leupeptin, and 1 #g/#l soybean trypsin inhibitor) and frozen on 
dry ice. After thawing, the cleared supernatant (10 min microfuge) 
was used for immunoprecipitation with the anti-Pim-1 COOH- 
terminal peptide serum, bound to protein A-Sepharose beads (Phar- 
macia Biotech Europe, Brussels,  Belgium). Immunoprecipitation 
buffer was  10 mM sodium phosphate, pH 8.0, 150 mM NaC1, 5 
mM CHAPS,  and 14 mM B-ME. Kinase assays with antibody- 
immobilized Pim-1 proteins were Performed in 20 mM Pipes, pH 
7.0, 15 mM MnCI~, 7 mM/~-ME, 0.25 mM B-glycerophosphate 
0.4 mM spermine,  and 10/~Ci 3,-[32p]ATP (3,000 Ci/mmol) for 
30 min at 30~  before being analyzed by 15%  SDS-PAGE. 
Flow Cytometry.  This was done essentially as described (9, 23). 
Most antibodies used were directly conjugated to fluorochromes 
or biotinylated and some were used as culture supematants (CDllb, 
JORO,  ICAM2).  Biotinylated monoclonals were revealed by a 
second incubation with streptavidin-fluorochrome, unconjugated 
monoclonals by second incubation with mouse anti-rat-K-FITC. 
Fluorochromes used are FITC or PE. The cells were analyzed on 
a FACScan  |  (Becton Dickinson & Co., Mountain View, CA). An- 
tibodies used are CD45tL/B220 (6B2), BP1 (6C3), CD43 ($7), HSA 
(M1/69), CD3 (145-2Cll), CD4 (RM4-5), CD8 (53-6,7),  TCP,- 
cx/B (H57-597), CD44/Pgp-1 (IM7), and Gr-1 (RB6-8C5), all from 
Pharmingen (San Diego, CA). Sca-1 and PB76 (G-5-2) (24) were 
a gift from A. Strasser (Walter and Eliza Hall Institute, Melbourne, 
Australia); JORO30-8 and JORO75 (25) were gifts of R. Palacios 
(Basel Institute of Immunology, Basel, Switzerland); and ICAM- 
2/Lgp55 (PA3-795.4.16)  (26) was a gift from W. Golde (Univer- 
sity of Colorado, Denver, CO). Other antibodies used were as de- 
scribed before (9,  23). 
Colony Assays.  Agar cultures of mouse bone marrow cells (27, 
28) were performed by plating 5  x  104 bone marrow cells from 
2-4-too-old mice in 1 ml medium containing 0.25% agar in 3.5- 
cm dishes. Cells were plated in Fischer's medium with 20% horse 
serum (GIBCO BILL, Gaithersburg, MD) in the presence of 20% 
L cell conditioned medium (M-CSF) or the cells were plated in 
RPMI  1640  (Flow  Laboratories,  Irvine,  CA)  with  20%  FCS 
(GIBCO BRL), 5  x  10  -5 M B-ME and growth factors (B cells). 
Growth factors were rlL-7,  10 ng/ml, Escherichia coli-produced 
rrSCF 164, 35 ng/ml, gifts of L. M. Souza, and K. Zsebo, Amgen 
Biologicals  (Thousand Oaks,  CA),  or  yeast-derived  rMGF,  35 
ng/ml, gift of B. Overell, Immunex (Seattle, WA) and LPS (Difco, 
Detroit, MI), 30/xg/ml. Plates were incubated for 8 d in a fully 
humidified incubator with  a 5%  COs  atmosphere after which 
colonies of more than 50 cells were counted. Outbred null mu- 
tants and their controls were assayed as pools of two or three bone 
marrows;  all other mice were assayed individually. 
Tissue Culture.  Whitlock-Witte type long term bone marrow 
cultures were established  and maintained essentially  as described 
(29).  For short-term primary B cell cultures  106 bone marrow 
cells, flushed from femurs and tibiae, were incubated in 5 ml long- 
term culture (LTC) medium plus growth factors  in a T25 flask 
(Costar Corp., Cambridge, MA). LTC medium is RPMI 1640 sup- 
plemented with 5% FCS, 5  x  10 -5 M/~-ME, and penicillin  and 
streptomycin. Growth factors used were 10% 3T3-IL7 conditioned 
medium (CM) and 60 ng/ml steel factor (SF  1) (rrSCF164). Factor- 
dependent subcultures  and cell lines derived from LTC were grown 
in LTC medium supplemented with 10% 3T3-IL7 CM, SF (rMGF 
or rrSCF 164, 22 ng/ml), 1% X63-IL3 CM and 1% X63-IL5 CM 
(30); for short-term stimulations purified rlL-7 was used at 10 ng/ml 
(Amgen Biologicals). For short-term stimulation of cell lines, cells 
were spun out of their culture medium, washed in LTC medium 
without added factors, and resuspended in LTC medium with ap- 
propriate factors.  Cells were incubated at the indicated densities, 
usually 10  s cells per ml in flat-bottomed 96-well  plates  (Falcon, 
Lincoln Park, NJ), 200 #1 per well. After stimulation, living cells 
were quantitated using an improved Neubauer hemocytometer (W. 
Schreck, Hofheim, Germany) in the presence of trypan blue or a 
Sysmex Toa F800 microcellcounter (Kobe, Japan). In vitro differen- 
tiation attempts of LTC-derived cell lines were performed by cocul- 
turing these cells with stromal cell lines in the presence or absence 
of added growth factors. The latter included 10% 3T3-IL7 CM, 
10 ng/ml SF, and 30/zg/ml LPS. Stromal cell lines used,  which 
were grown in LTC medium, were PA6 and ST-2 (31), gift of A. 
Rolink (Basel Institute of Immunology) and RP.0.10 (32), gift of 
R. Palacios. In vivo differentiation experiments were performed 
by injecting 5  x  106 cells into nonirradiated SCID  mice,  pur- 
chased from Bomholtgard Ltd. (Ry, Denmark). The mice were 
killed 4-8 wk later, and the hematopoietic organs were analyzed 
by flow cytometry. 
Recombinant Growth Factors.  Growth factors were used at the 
concentrations given, unless  indicated otherwise.  Recombinant 
human Ib6 and l'b7, 10 ng/ml, recombinant human Ib8, 50 ng/ml, 
and  rat  SCF  164, 10  ng/ml,  were  gifts  of Amgen  Biologicals. 
Recombinant mouse MGF, 22 ng/ml,  was  a gift of Immunex. 
Recombinant human IL-lcx (33),  100 U/ml, was donated by A. 
Stern (Hoffmann-La Roche, Nutley, NJ). Recombinant mouse Ib9 
(34), 5 ng/ml, was a gift of Jacques van Snick (Ludwig Institute, 
Brussels, Belgium). Media from L929b cells, gift of T. M. Dexter 
(Paterson Institute, Manchester, UK), were used at 20% as a source 
of murine M-CSF,  CM from X63 cell lines producing IL-3 and 
I1.,5 (30), used at 1%, were donated by A. Strasser, whereas mouse 
Ib7-producing 3T3 cells, whose CM was used at 10%, were do- 
nated by A. Rolink (35). Recombinant mouse leukemia inhibitory 
factor (ESGRO) was purchased from Amrad (Kew, Australia) and 
used at 1,000 U/ml, recombinant human insulin-like growth factor 
1 (IGF-1) used at 10 ng/ml, was purchased from Boehringer Mann- 
heim (Mannheim, Germany). 
Results 
B Cell Populations in Bone Marrow..  Comparison of the total 
number of bone marrow cells recovered from Pim-1 mutants 
and  their wild-type controls revealed no significant differ- 
ences. Flow cytometric analysis of the B lymphoid popula- 
tions present in the bone marrow of the various Pim-1 mu- 
tant mice showed no clear differences in pre-B cells (B220  aat 
slg-)  (Table 1). Also, a more detailed analysis (36) did not 
reveal differences (20). Differences were noted in the size of 
the mature B cell compartment (B220bns  ht slg +) present in 
El~-Pim-1 transgenic mice, which was reduced to half of that 
seen in wild-type mice (Table 1). Pim-l-deficient  mice did 
not differ from their wild-type littermates in this  respect. 
1666  B Cell Development in Mutant Pim-1 Mice Table  1.  B  Cell Populations in Bone Marrow 
Total  Pre-B  cells  B  cellst 
bone marrow  B220+slg -  B220+slg + 
E#-Pim-1  (n  =  8)  9.6  _+  1.4"  15.8  _+  4.9t  4.6  _+  0.8 
Wild  type  (n  =  6)  9.8  _+  1.9  18.8  _+  5.1  8.0  _+  0.9 
Pim-1  deficient 
(n  =  8)  6.3  +_  0.6  19.7  +_  4.7  8.2  _+  1.6 
Wild  type(n  =  8)  6.4  +  1.4  26.1  _+  4.4  6.9_+  1.2 
Distribution of B-lymphoid cells as determined by flow cytometry on 
bone marrow of mature (1-3-mo-old)  mice. Results are given as means  +_ 
SD. The data  on El~-Pim-1 transgenic  mice were obtained  from heter- 
ozygotes, homozygous Pim-l-null mutant mice were both outbred (n  = 
6) and inbred (n  =  2). 
* Calls  ( x 10- 7) isolated  from both femurs  and  tibiae. 
* Percent  total bone marrow. 
Figure  1.  B lymphoid colony assays on bone marrow of mutant Pira-1 
mice. The results,  means  _+  SEM,  are given relative  to the number of 
colonies induced from wild-type bone marrow per experiment.  (A) Colo- 
nies seen in the bone marrow of 19 outbred mice, homozygous for the 
Pim-1 null allele. (B) The same stimulations  performed  on bone marrow 
from five mice homozygous for the Ev-Pira-1 transgene. (C) The number 
of CFC found in four different mutant Pira-1 mice in response to stimula- 
tion with lymphoid and a myeloid control (M-CSF), growth factors. As- 
sayed were five homozygous targeted  (-/-),  five heterozygous  targeted 
(-/+), and five wild-type (+/+) mice, all 129/Ola inbred.  Variation for 
the latter group is indicated  by the lower error bars. Results  also given 
are for 12 wild-type (+/+, upper error bars),  12 beterozygous  transgenic 
(T+/+), and five homozygous E#-Pim-1 transgenic  mice. The transgene 
is present on a B.CBA background.  Similar numbers  of CFC were found 
in wild-type mice of the various  genetic  backgrounds. 
Bone Marrow Growth Factor  Response in Colony Assays.  The 
number of different B lymphoid colony-forming cells (CFC) 
present in bone marrow from mice lacking (Fig. 1 A) or over- 
expressing Pim-1 (Fig. 1 B) were determined. In bone marrow 
of Pim-l-defident mice, the number of colonies obtained with 
either IL-7, which induces pre-B cell colonies (28), or with 
IL-7 and SF, which also stimulates  more primitive  cells  to 
differentiate into pre-B cells (37), is reduced to approximately 
one third of wild-type levels. A reduction is also seen in colony 
size (see also below). In contrast, mature B cell colonies formed 
upon stimulation with LPS (38) are normal both in number 
and  size. 
In E#-Pim-1  transgenic  mice,  there is an increase in  the 
number of colonies formed in response to the combination 
of IL-7 and SF. A  moderate increase is seen in stimulations 
with IL-7 alone, whereas there is actually a decrease in the 
number of LPS-responsive CFC. The latter is corroborated 
by flow cytometry (see above). No clear effect on colony size 
was noted. Interestingly, homozygous transgenic mice clearly 
differed in the severity of their phenotype from the heterozy- 
gous mice. A similar effect has been noted for the phenotype 
described before for these mice. T cell lymphomagenesis, with 
homozygous  mice  displaying  a  much  higher  incidence 
(',~40%  per yr)  than  heterozygous mice (5-10%  per yr). 
Whereas a strict correlation is seen between Pim-1 expres- 
sion levels  (shown below) and  the  number  of colonies in- 
duced by IL-7 and SF (Fig.  1 C).  This is not  seen for the 
induction of myeloid (macrophage) colonies by M-CSF (39). 
A possible exception are homozygous transgenic mice, where 
the numbers  are reduced. 
The data show that in Pim-l-defident  mice, the number 
of early,  IL-7  +  SF responsive, B lymphoid cells is reduced 
whereas the numbers of mature,  LPS responsive, B cells in 
bone marrow are normal  In mice overexpressing Pim-1 the 
opposite is seen, and the numbers of the IL-7  +  SF respon- 
sive early B cell progenitors are increased,  whereas the number 
of LPS-responsive B  cells,  is reduced. 
Bone Marrow Growth Factor  Response in Liquid Cultures.  Be- 
cause pre-B cell colonies showed differences in size, we moni- 
tored their  growth  potential  by directly stimulating  bone 
marrow in liquid cultures (37). Clear differences were noted 
when unfractionated bone marrow from different Pim-1 mu- 
tants  was  stimulated  with  IL-7  +  SF or IL-7  alone.  The 
growth of bone marrow  cells  from mice heterozygous for 
the Pim-1 null allele  was significantly reduced when com- 
pared with that of  wild-type llttermates,  whereas a more drastic 
reduction was seen with  the bone marrow of homozygous 
null  mutant  mice (Fig.  2).  Subculturing  (for up  to several 
weeks) did not improve growth in the Pim-l-deficient  cul- 
tures, although wild-type cultures continued to grow with 
similar  kinetics  (data  not  shown). 
Bone marrow of E~-Pim-1 transgenic mice showed an in- 
creased response with IL-7  +  SF (Fig. 2), whereas the effect 
of IL-7 only did not differ significantly from those of wild- 
type littermates.  Upon subculturing,  differences in growth 
rate disappeared  (data  not  shown).  This  indicates  that  the 
increased production initially seen reflects differences in the 
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Figure 2.  Stimulation  of Pim-1 mutant bone marrow ceils  by B lymphoid  growth factors in liquid  culture. Growth was stimulated with 10% 3T3-IL-7 
CM with or without SF (60 ng/ml). Living cells were qnantitated daily in the presence of trypan blue. SD are shown when larger than the marker 
symbol. Top panels show stimulations recorded in cultures  from five wild-type,  two heterozygous null mutant, and five homozygous  null mutant 
mice. (Left) Stimulation  with Ib7; (middle) with Ib7 +  SF; and (right) flow cytometric analysis of two cultures stimulated with IL-7 +  SF. Left peaks 
show PBS control whereas the right peaks represent staining with FITC-conjugated  B220. Cells were cultured 10 d in the presence of IL-7 and SF. 
Bottom panels show similar stimulations using the bone marrow from three wild-type and three heterozygous E~-Pim-1 transgenic mice. Stimulation 
was with I1.-7 (left) or Ib7  +  SF (middle). (Right) The B220 surface phenotype of two cultures. Left peaks show PBS control whereas the right peaks 
show staining with biotinylated B220 revealed  by stmptavidin-PE.  Higher fluorescence  intensity than in top panel is caused  by biotin-streptavidin  amplification. 
Cultures were stimulated  8 d with Ib7 and SF. 
number  of responsive cells  present  in bone  marrow  rather 
than  differences  in  growth  rate. 
Flow cytometric analysis of the cells obtained in these cul- 
tures  (Fig.  2) shows that virtually  all of the cells produced 
are pre-B  cells  (B220 +,  slg-).  This  also  holds  true for all 
Pim-1 mutant cultures,  including those with a severely im- 
paired response to IL-7, demonstrating that, as in the colony 
assays, Pim-I null mutants can still recognize and use IL-7. 
Pim-1 Expression in Murine Pre-B Cells. To determine whether 
these differences correlated with the Pirn-1 protein levels, cells 
were harvested after 7-10 d of stimulation and the Pim-1 pro- 
teins were immunoprecipitated  and  labeled  with  np in  an 
autophosphorylation  reaction (5).  As shown in Fig.  3,  the 
amount of Pim-1 protein detected in this way correlated with 
Figure  3.  Pim-1 protein expression levels  in mutant Pim-1 mice. Pim-1 
levels were determined by autophosphorylatinn with 32p of the antibody- 
immobilized  proteins in a kinase assay. The 44-kD Pim-1 protein is over- 
represented since this is a much better substrate for autophosphorylation 
(5). 2.5  x  106 primary pre-B cells, as in Fig. 2, were analyzed. (Lanes 
I and 2) Homozygous null  mutants (lanes 3 and 4) heterozygous null  mu- 
tants; (lanes 5-8) wild-types; and (lanes 9 and 10) heterozygous E/~-Pim-1 
transgenics. The cultures  assayed in lanes 1-6 are derived from inbred 
129/Ola mice and were stimuhted with II.-7, whereas the cultures assayed 
in lanes 7-10 are derived from B.CBA mice and they were stimulated with 
IL-7 and SF. 
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Figure 4.  Rescueofthenullmu- 
tant phenotype  by introduction  of 
the  WT-Pim-1 transgene. Bone 
marrow cells from mice, two per 
group, homozygous  for the Pim-1 
null  allele,  with or without  the WT- 
Pim-1 transgene" and  wild-type, 
were tested  for the presence  of  CFC 
responsive  to Ib7 (left),  the growth 
response to I1r  in liquid cultures 
(middle), and the Pim-1 protein  levels 
in 5 x  106 pre-B cells from Ib7- 
stimulated  cultures (right). (Lanes/) 
Immunoprecipitations;  and (hnes  B) 
immunoprecipitations  in the pres- 
ence of excess amounts  of  blocking 
peptide. The proteins are visualized 
by autoradiography  after  autophos- 
phorylation  in  the  presence of 
3,[32p]dATP. 
the Pim-1 genotype. No clear differences in Pim-1 expression 
were noted between cells stimulated with IL-7 or IL-7 plus SF. 
Rescue of the Impaired Response in Pim-l-deficient Mice b  7 
Introduction ofa  Transgene.  To prove that the defects noted 
in Pim-l-deficient mice resulted from the absence of Pirn-1 
and not from another, possibly linked, mutation present in 
the embryonic stem cells, we crossed the Pim-l-deficient  mice 
with mice carrying a wild-type Pim-1 transgene, WT-Pirn-1. 
In the resulting mice, which were homozygous for the Pim- 
1 null allele and heterozygous for the WT-Pim-1 transgene, 
the IL-7 response had indeed been rescued (Fig. 4). Flow cyto- 
metric analysis of the cultures (data not shown) confirmed 
the  presence  of  the  expected  population  of  pre-B  cells 
(B220 +, sIg-). When Pim-1 protein levels were analyzed in 
ceUs derived from these cultures (Fig. 4) close to normal levels 
of both Pim-1 proteins were seen in ceils derived from null 
mutant mice carrying the WT-Pirn-1 transgene. This con- 
clusively shows that the impaired IL-7 response is caused by 
the absence  of the Pim-1 proteins. 
Whitlocle-Witte Type Long-Term B Lymphoid Cultures Can 
be Established  from Mutant Pim-1 Mice.  In view of the fact 
that the drastically reduced growth factor responses of early 
B cells of Pim-l-deficient mice in vitro are not reflected in 
reduced populations in vivo, we studied more complex cul- 
ture systems, to see whether compensating mechanisms which 
normalize B cell levels in vivo could be mimicked in vitro. 
For this purpose,  Whitlock-Witte type long-term B lym- 
phoid cultures (29) were established  from bone marrow of 
the different Pim-1 mutants and their wild-type controls. In 
this system, whole bone marrow is cultured without added 
growth factors and prolonged B lymphopoiesis takes place, 
supported by stromal cells. All the Pim-1 mutants tested, 
ranging from homozygous for the null allele to heterozy- 
gous for the El~-Pim-1 transgene, were able to establish such 
cells  (.input) 
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Figure  5.  Growth factor re- 
sponse of cells produced by long- 
term B lymphoid cultures. (Left) 
Nonadherent  cells, produced  by es- 
tablished Whitlock-Witte  cultures 
derived from wild-type  or hetero- 
zygous E#-Pira-1 transgenic  mice, 
cultured  in the presence  of  IL-3,  I1.-5, 
IL-7, and SF. Cells  were  quantitated 
using  a hemocytometer  in the pres- 
ence of trypan blue. Shown  is the 
establishment  of WSC905. (Right) 
Expression of surface markers, de- 
termined by flow cytometry, on 
WSC905. Similar expression pat- 
terns were seen on  agar-derived 
clones from this cell line. 
1669  Domen  et al. cultures. There are no obvious differences between the var- 
ious genotypes, showing that the differences described above 
cannot be seen when complex cell-cell interactions are al- 
lowed between stromal and lymphoid cells. 
Characterization of Cell Lines Derived from  Whitlock-Witte 
Cultures.  We tested nonadherent cells from such cultures 
for their response  to various growth factors.  In the absence 
of growth factors,  and even in the presence  of long-term 
cultures-CM, the cells died rapidly.  However, in the pres- 
ence of certain growth factors, rapid and continuous growth, 
allowing cloning in soft agar, was induced in cells derived 
from all four independent E#-Pim-1 transgenic cultures tested, 
but not from wild-type cultures (Fig. 5). The surface markers 
of these cells showed a pre-B  cell phenotype (Fig.  5).  No 
staining was observed for CDllb, GtL-1, JORO-30-8, JORO 
75, CD3, CD4, and CD8. CD43 ($7) expression was either 
low or absent. Cell identity was confirmed by ILNA and DNA 
analysis, which showed high expression of the transgene, ~,5 
and rag-l,  and rearrangements of the Ig H  chain, but not 
L chain or TCR/~ chain gene (data not shown). Attempts 
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Figure 6.  Characterization  of growth factor requirements of EIx-Pira-1 
transgenic cell lines derived  from Whitlock-Witte  cultures. Illustrated  is 
cell line WSC704. (.4) Titration of the proliferative  response to IL-7 in 
the presence of saturating  amounts  of SF. Stimulation  for 3 d, initial  den- 
sity 10  s cells per ml. (B) Titration of the response to SF in the presence 
of saturating  amounts  of Ib7, initial  density  10  s cells/m1, stimulation  for 
3 d. (C) Titration  of the response to IGF-1 in the presence of saturating 
amounts of IL-7. Initial  density  105 cdls/ml, stimulation  for 4 d. The re- 
sponse of cell line WSC905 is shown. (D) Comparison of proliferation 
in response to Ib7  + SF (thin dashed line) or IL-7 + IGF-1 (thick line). 
(E) Response to triple growth factor  combinations.  Stimulation  without 
factors, or saturating  amounts  of IL-7 and SF, are shown  on the left (white 
bar). (Hatched  bars) Stimulations  with IL-7, SF, and the growth factor  indi- 
cated at the bottom. An increase is seen with some, but not with other 
growth factors.  Means _+ SD are shown  of a representative  assay  in duplicate. 
to grow cells with a similar phenotype directly from bone 
marrow using the same growth factors failed. 
The cells are dependent on simultaneous stimulation by 
IL-7 and SF (Fig.  6 A  and B). IL-7 could not be replaced 
by any of the other growth factor (combinations) tested. SF, 
however,  could be replaced  by IGF-1 (Fig.  6 C), although 
the growth rate was less than in response to IL-7 and SF (Fig. 
6 D).  IGF-1  did not further increase  IL-7  +  SF induced 
growth, unlike some other factors  (Fig.  6 E). 
Interestingly, unlike what has been reported for various 
other progenitor B cell lines (35),  these seem to be blocked 
in differentiation, since attempts to induce slg expression using 
cocultivation with  the  stromal  cell  lines  ST2,  PA6,  and 
RPO.10, in the presence  or absence of IL-7 and LPS, have 
failed. A similar lack of differentiation was observed in vivo, 
when 5  x  106 cells were injected into SCID mice. 
Discussion 
Pim-I Expression Levels Determine the Size of B Cell Progen- 
itor Compartments in Bone Marrow..  Murine P/m-l, whose over- 
expression  is associated with a variety of tumors, encodes  a 
serine/threonine-specific protein kinase (5). We have shown 
previously that aberrant levels of Pim-1 affect IL-3-induced 
proliferation of  bone marrow-derived mast cells in vitro (21). 
Here we have used mouse mutants to show that it is involved 
in vivo in the regulation of early steps of B lymphopoiesis. 
This is illustrated most clearly by the observation that the 
number of SF and IL-7 responsive  early-B lymphoid CFC 
in bone marrow directly follows the expression levels of  Pim-1. 
The growth rate in response  to these factors is impaired in 
the absence of Pim-1. We also found that overexpression facili- 
tates the establishment of factor-dependent early lymphoid 
cell lines  that seemed  to be blocked in differentiation. 
IL-7 is a stromal cell factor with growth-promoting ac- 
tivity for B cell precursors (28-40).  More primitive B cells 
require an additional stimulus, such as SF (41-43)  or IGF-I 
(44).  To identify additional important factors,  mouse mu- 
tants in which the responses to known factors are impaired, 
can be important tools. Pim-l-deficient  mice, which show 
a severely impaired response to IL-7 and SF, but which are 
capable  of normal B lymphopoiesis in vivo and in LTC in 
vitro, will constitute an excellent model system to search for 
such factors. 
The earliest  B cell precursor compartment assayed (IL-7 
+  SF responsive) was the most profoundly affected. CFU-S 
assays on E#-Pim-1 transgenic mice have shown that this very 
early nonlymphoid committed, precursor population is not 
increased  (Domen, J., E. Spooncer,  and T. M. Dexter, un- 
published observations),  suggesting that these effects of aber- 
rant Pim-1 expression do not extend to the most early hema- 
topoietic cell compartment. The number of mature B cells 
in bone marrow (B220 +,  slg § , responsive  to LPS),  while 
normal in Pim-l-deficient mice, is reduced in EIz-Pim-1 trans- 
genic mice.  A  decrease in mature B cell numbers has also 
been observed in E/~-myc transgenic mice, here concomitant 
with the increase in pre-B  cell numbers (45).  The absence 
of significant changes in the periphery of Pim-1 mutants (9, 
1670  B Cell Development in Mutant Pim-1 Mice 20) may be explained by an increased life span or prolifera- 
tion of relatively long-lived mature B cells (46).  This is also 
observed in  the other null  mutants with impaired B  cell 
production, such as c-abl (47) and )~5 mice (48).  The lack 
of correlation between the size of the pre-B cell compart- 
ment as defined by flow cytometry and the number of CFC 
present suggests that only a distinct subset of the pre-B cells 
are clonogenic precursors. The total number of pre-B cells 
in the bone marrow may be limited through other mecha- 
nisms, like the available bone marrow space. 
Intriguingly, in marrows with the highest Pim-1 expres- 
sion, a reduction in M-CSF responsive ceils is observed. This 
reduction may reflect a selective differentiation of common 
precursors, such as described for fetal liver (49),  towards the 
lymphoid lineages, or a more direct effect on macrophage 
differentiation, e.g., by affecting common mediators specific 
for the SF and M-CSF response. 
Defects Caused by the Targeted  Disruption of  Pim-1 Locus Can 
be Rescued in Trans.  The defects seen in the null mutant mice 
are likely caused by the inactivation of Pira-1, as the same 
phenotype has been observed in mice obtained from different, 
independently targeted, ES cell clones. However, in order to 
formally prove that the phenotype observed was the result 
of Pim-1 inactivation, we introduced a wild-type Pim-1 trans- 
gene. This transgene indeed rescued the effects seen, which 
can thus be completely ascribed to Pim-1. 
Pim-1 Functions in a Dose-dependent Fashion.  Pim-1 exerts 
its function in a dose-dependent manner, over a large dosage 
range, both in the assays described and in lymphoma inci- 
dence. Dosage-dependent phenotypes are displayed by some 
protein kinases, like regulators of mitosis in yeast (50), some- 
times despite the presence of redundantly acting proteins (51), 
whereas  the  activity  of other  kinases,  e.g.,  most  proto- 
oncogenes, is strictly regulated (52).  The highly inducible 
and short-lived RNA  (11-13)  and extremely short protein 
half-life (5) suggest, in line with the dosage-dependence seen, 
that Pim-1 might function as a constitutively active enzyme, 
although it cannot be excluded that activation is required, 
but not rate limiting. 
Implications for the Function of  Pim-l,  The in vitro analysis 
ofB lymphopoiesis in the Pim-1 mutant mice presented here 
has shown for the first time that Pim-1  is involved in the 
responses  to  different growth  factors which  act  on early 
B-lymphoid compartments. Absence of Pim-1 does not lead 
to a total lack of responsiveness to the early B-lymphoid growth 
factors IL-7 and SF, whereas overexpression does not abro- 
gate factor dependency, similar to the effects noted for IL-3 
(21). This is unlike what has been reported for protein tyro- 
sine kinases which can abrogate growth factor dependency 
(53), indicating that Pim-1 is a modulator rather than a medi- 
ator for the response to these factors. Whereas Pim-l-deficient 
cells show reduced growth rates when propagated in the pres- 
ence of IL-7 or IL-3, we have not observed increased growth 
rates in cells overexpressing Pim-1. This suggests that Pim-1 
levels in wild-type cells are already saturating for the pro- 
liferation-inducing signals.  However, this does not seem to 
be in agreement with the phenotype of overexpression in vivo, 
an increasing tendency to develop lymphomas. Therefore, regu- 
lation of the size of early compartments by Pim-1 probably 
does not reflect a direct involvement in the proliferative re- 
sponse to growth factors.  More likely, Pira-1 is involved in 
transducing signals  that can halt or impair differentiation. 
This would explain the coincidence of Pim-1 levels and early 
B-lymphoid colony forming capacity of bone marrow and 
the behavior of cell lines obtained from overexpressors. It would 
also explain how Pim-1 functions as an oncogene when over- 
expressed, as expanded progenitor pools would increase the 
size of the cell compartment critically important to the ac- 
cumulation of mutations.  Detailed biochemical analysis  is 
needed to fully resolve the mechanism of action of the Pim-1 
proteins. Furthermore, it remains to be determined ifPim-1 
fulfills a similar function in the T cell lineage.  The involve- 
ment of Pim-1 in T cell lymphomagenesis indicates that this 
is probably the case. 
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